opdivo_1_1

BMS unveils strong five-year efficacy data for Opdivo in lung cancer

pharmafile | September 11, 2019 | News story | Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma 

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase 3 studies in the treatment of previously treated advanced non-small cell lung cancer (NSCLC).

BMS’ immunotherapy demonstrated overall survival rates of 13.4% across all patient subgroups after five years of treatment, compared to just 2.6% with docetaxel. Furthermore, 32.2% of patients who achieved an objective response to Opdivo continued to respond after five years of treatment, whereas no patients who achieved an objective response with docetaxel still saw a response after the same period.

Additionally, median duration of response in patients treated with Opdivo was 19.9 months, compared just 5.6 months with docetaxel, while the therapy’s safety profile was also found to be consistent with previous data in second-line NSCLC.

“Since the U.S. Food and Drug Administration approval in second-line non-small cell lung cancer in 2015, Opdivo has become an important treatment option for this population of patients, who historically faced five-year survival rates of less than 5% when treated with standard chemotherapy,” remarked Dr Sabine Maier, Development Lead, Thoracic Cancers, at Bristol-Myers Squibb. “The long-term survival outcomes from these two studies in a large patient population add to the body of evidence supporting the durability of Opdivo-based regimens, which has now been demonstrated across multiple tumour types and lines of therapy.”

Matt Fellows

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

national-cancer-institute-kmvohcb-w5g-unsplash_1

AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Latest content